In Q2 2026, Elanco Animal Health demonstrated solid operating cash flow improvement and strategic investment in biologic manufacturing capacity. While facing intensified generic competition notably on branded products like Seresto, and regulatory challenges restricting antibiotic use in farm animals, Elanco’s diverse pet and farm animal product portfolio provides resilience. The company’s ongoing acquisition of AHV strengthens its foothold in antibiotic alternatives for livestock, though its substantial debt load and restructuring remain key financial watch points.